Home > News > Small: old drug new use: clinically approved carbon nanoparticles for free radical scavenging to reduce intestinal radiation damage

Small: old drug new use: clinically approved carbon nanoparticles for free radical scavenging to reduce intestinal radiation damage

wallpapers News 2020-12-28

acute radiation enteritis is an inevitable secondary intestinal injury in patients with abdominal pelvic malignant tumor radiotherapy because the intestinal tract especially the small intestine is one of the most sensitive organs to radiation. Therefore the radiation dose tolerance of intestinal tissue adjacent to abdominal pelvic malignant tumors severely limits the high-dose radiotherapy for tumors which greatly limits the killing effect of radiotherapy on tumors. Therefore the development of radioprotective agents to reduce the radiation damage of small intestinal tissue can not only improve the quality of life of patients but also effectively increase the radiation dose at the tumor site so as to achieve more effective tumor treatment effect. Although it has been reported that some nano materials have certain radiation protection properties for biological tissues especially carbon nano materials their derivatives such as fullerenol graphene whose stable structure good free radical scavenging ability have been confirmed by a large number of studies these newly developed nano radioprotectants still face great challenges in clinical transformation Application It's a challenge.

to solve the above problems Gu Zhanjun's research team of Institute of high energy physics Chinese Academy of Sciences through the strategy of "new use of old drugs" for the first time approved the only carbon nanomaterials in clinical use by China food drug Administration (CFDA) - kanalin carbon nanoparticles suspension injection (national drug approval word h20041829 carbon nanoparticles suspension) Injection (CNSI) is a novel nano radioprotective agent for the radiation protection of intestinal tract (mouse model). CNSI is clinically used for tracing the regional draining lymph nodes of gastric cancer. At present it is used for lymph node localization or parathyroid differentiation in tumor surgery. More than 100000 people use CNSI every year which has good biological safety. CNSI is a kind of graphene analogues with a large number of conjugated benzene rings abundant hydrophilic groups. Its special physical chemical properties make it have a good potential for intestinal radiation protection. This work shows that CNSI has the following three advantages in intestinal radiation protection: 1) CNSI has strong conjugated structure abundant hydrophilic groups which makes it have good water solubility efficient free radical scavenging ability can scavenge many types of free radicals; 2) CNSI can meet the requirements of oral drugs because it is still effective in the harsh environment of gastric acid It can maintain good chemical stability effective free radical scavenging ability without a lot of degradation inactivation. At the same time CNSI can be excreted through the intestinal tract to reduce its long-term toxicity; 3) CNSI can remove radiation-induced free radicals in the gastrointestinal tract protect the integrity of intestinal villi thus maintaining the balance of intestinal flora alleviating the symptoms of radiation enteritis. This research work not only provides a new nanotechnology solution for gastrointestinal radiation protection but also further exps enriches the new application fields scenarios of clinical drug CNSI.

published in small

TRUNNANO (aka. Luoyang Tongrun Nano Technology Co. Ltd.) is a trusted global chemical material supplier & manufacturer with over 12 years' experience in providing super high-quality chemicals and Nanomaterials. Our company has successfully developed a series of powder materials (including oxides, carbides, nitrides, single metal, etc.), high-purity targets, functional ceramics, and structural devices. OEM service is available. Please contact us if necessary.
Say something
  • All comments(0)
    No comment yet. Please say something!